A Prospecitve Multicenter, Observational Registry Study

← catalyst calendar

NCT07481526 · readout in 864 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

—

Status

Recruiting

Study type

Observational

Enrollment

3,000estimated

Sites

Country

China

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-02-27

actual

When the study began enrolling

Primary completion

2028-12-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-12-30

estimated

The whole study's end, after follow-up

First posted

2026-03-19

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-13

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Chronic Kidney Disease

Primary outcomes

what the primary-completion date above is the date OF

Proportion of CKD patients with HP, HF, HTN, and HK at baseline, respectively

measured baseline

Adoption rate of medications (e.g., Endothelin receptor antagonists [ERA], MRA, RASi, SGLT2i)

measured Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients with HK

measured Week 0 to week 96

Clinical outcomes of CKD patients with HK

measured Week 0 to week 96

Clinical outcomes of CKD patients with HK

measured Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

measured Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

measured Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

measured Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

measured Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

measured Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

measured Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

measured Week 0 to week 96

Clinical indicators for CKD patients with HP and HTN

measured Week 0 to week 96

Clinical indicators for CKD patients with HP and HTN

measured Week 0 to week 96

Clinical indicators for CKD patients with HP and HTN

measured Week 0 to week 96

Clinical indicators for CKD patients with HF

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

measured Week 0 to week 96

Clinical indicators for CKD patients with HF

measured Week 0 to week 96

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed